{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:25:13Z","timestamp":1763465113402,"version":"3.45.0"},"reference-count":32,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"internal start-up fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The molecular and clinical underpinnings of worse overall survival outcomes with liver metastasis of CRC are not well-defined. We therefore aimed to investigate molecular and clinical characteristics of liver metastasis of CRC in this comparative study. Methods: Patients diagnosed with metastatic CRC from 2014 to 2022 were identified using the institutional molecular database of CRC. Demographic, clinical, and molecular data were collected and analyzed using Fisher\u2019s exact tests for categorical variables, Kaplan\u2013Meier analysis, and multivariate Cox regression analysis. Results: We identified 299 total patients with metastatic CRC, including patients with liver metastasis (n = 205) and non-liver metastasis (n = 94). We observed a significantly higher incidence of liver metastasis among patients with colon cancer compared to rectal cancer (74% vs. 48%, p = 0.00013). There was no significant difference in the incidence of common driver mutations, including KRAS, BRAF, and TP53, in the liver versus non-liver metastasis cohorts. There was a trend toward worse median overall survival among patients with liver metastasis, though this was not statistically significant (42.2 vs. 47.6 months, p = 0.27). Liver metastasis was identified as a significant predictor of shorter time on frontline therapy (HR 1.82, p &lt; 0.001), a surrogate for treatment response, with a median time of 13 months from first- to second-line treatment compared to 19.7 months in the non-liver metastasis cohort (p = 0.00098). KRAS mutations were a significant predictor of worse survival in the liver metastasis cohort only (HR 2.01, p &lt; 0.001), while BRAF mutations were a significant predictor in the non-liver metastasis cohort (HR 3.42, p = 0.006). Conclusions: Liver metastasis of CRC is associated with shorter time on frontline therapy, indicative of potential chemotherapy resistance. Given similar incidence of molecular alterations in patients with liver metastasis and non-liver metastasis, therapeutic resistance may instead be related to the tumor microenvironment of the liver. Most notably, this is the first study to reveal that despite a similar incidence of molecular alterations, driver alterations including BRAF and KRAS mutations may have a distinct impact on survival outcomes depending on the site of metastasis.<\/jats:p>","DOI":"10.3390\/cancers17223677","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:05:31Z","timestamp":1763463931000},"page":"3677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Comparative Study of Clinical and Molecular Features of Microsatellite Stable Colorectal Cancer With and Without Liver Metastases"],"prefix":"10.3390","volume":"17","author":[{"given":"Tara","family":"Magge","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"},{"name":"Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0328-3951","authenticated-orcid":false,"given":"Svea","family":"Cheng","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaichao","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA 15232, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-9094","authenticated-orcid":false,"given":"Masood Pasha","family":"Syed","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA 15232, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0861-2656","authenticated-orcid":false,"given":"Bhaghyasree","family":"Jambunathan","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"},{"name":"Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Mcfarquhar","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"},{"name":"Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Zinser Peniche","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"},{"name":"Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doga","family":"Kahramangil Baytar","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"},{"name":"Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-7096","authenticated-orcid":false,"given":"Aatur","family":"Singhi","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA"},{"name":"Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Halil","family":"Sahin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology & Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"ref_1","first-page":"145","article-title":"Colorectal cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Surveillance Research Program, National Cancer Institute (2025, June 01). SEER*Explorer: An Interactive Website for SEER Cancer Statistics, Available online: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.annonc.2023.04.015","article-title":"LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): The phase 3 LEAP-017 study","volume":"34","author":"Kawazoe","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and Treatment of Metastatic Colorectal Cancer","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17474124.2019.1663174","article-title":"Precision medicine for metastatic colorectal cancer: An evolving era","volume":"13","author":"Guler","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability\u2013High\/Mismatch Repair\u2013Deficient Metastatic Colorectal Cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability\u2013High Advanced Colorectal Cancer","volume":"383","author":"Shiu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study","volume":"40","author":"Lenz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1188","DOI":"10.1634\/theoncologist.2020-0161","article-title":"Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Nie, C., Lv, H., Chen, B., Xu, W., Wang, J., Liu, Y., Wang, S., Zhao, J., He, Y., and Chen, X. (2022). Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.917353"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2118416","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1\/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e230400","DOI":"10.1001\/jamanetworkopen.2023.0400","article-title":"Association Between Survival and Metastatic Site in Mismatch Repair\u2013Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2346094","DOI":"10.1001\/jamanetworkopen.2023.46094","article-title":"Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1200\/JCO.2021.39.15_suppl.3560","article-title":"Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)\/microsatellite stable (MSS) colorectal cancer (CRC)","volume":"39","author":"Fakih","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1200\/JCO.2023.41.16_suppl.3554","article-title":"Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis","volume":"41","author":"Cohen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/EDBK_349811","article-title":"Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues","volume":"42","author":"Sahin","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/oncolo\/oyae013","article-title":"The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review","volume":"29","author":"Guven","year":"2024","journal-title":"Oncologist"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"LBA8","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA8","article-title":"Results from a phase 1a\/1b study of botensilimab (BOT), a novel innate\/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)","volume":"41","author":"Fakih","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.gastro.2022.09.028","article-title":"Prospective, Multi-Institutional, Real-Time Next-Generation Sequencing of Pancreatic Cyst Fluid Reveals Diverse Genomic Alterations That Improve the Clinical Management of Pancreatic Cysts","volume":"164","author":"Paniccia","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/onco.13741","article-title":"Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer","volume":"26","author":"Sahin","year":"2021","journal-title":"Oncologist"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2022.03.026","article-title":"A phase I\/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer","volume":"169","author":"Kim","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1038\/s41388-023-02835-y","article-title":"Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer","volume":"42","author":"Kasi","year":"2023","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2025.43.4_suppl.207","article-title":"Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update","volume":"43","author":"Hissong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/1750743X.2025.2530853","article-title":"Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: A comprehensive review","volume":"17","author":"Sahin","year":"2025","journal-title":"Immunotherapy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2025.43.4_suppl.242","article-title":"A comprehensive study of clinical and molecular features in patients with metastatic colorectal cancer with and without liver mets","volume":"43","author":"Magge","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3677\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:21:36Z","timestamp":1763464896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":32,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17223677"],"URL":"https:\/\/doi.org\/10.3390\/cancers17223677","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}